Julie Yu

This profile gathers the share dealings of Julie Yu in Amicus Therapeutics, Inc. The record holds 11 filings, for trades running from 10 April 2014 to 15 June 2015.

In open-market terms, that means 2 purchases worth €40k on one side and 5 sales worth €300k on the other. Sales outweigh purchases by €260k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 2 share grants and 2 option exercises. So far in 2015, the count stands at no purchases and 3 sales.

The newest entry dates from 16 June 2015: an open-market sale of €103k, in Amicus Therapeutics, Inc. The latest purchase dates back some time: it was published 4,417 days ago, on 6 October 2014. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.